Energy Transfer Equity, L.P. (ETE) saw its value decrease by -0.36% as the stock dropped $-0.07 to finish the day at a closing price of $19.31. The stock was lighter in trading and has fluctuated between $4-$19.99 per share for the past year. The shares, which traded within a range of $19.25 to $19.65 during the day, are up by 17.3% in the past three months and up by 45.18% over the past six months. It is currently trading 8.46% above its 20 day moving average and 15.59% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $19.33 a share over the next twelve months. The current relative strength index (RSI) reading is 70.65.The technical indicator do not lead us to believe the stock will see more gains any time soon.
Energy Transfer Equity, L.P. provides diversified energy-related services in the Unites States. It owns and operates approximately 7,500 miles of natural gas transportation pipelines and three natural gas storage facilities in Texas; and approximately 12,300 miles of interstate natural gas pipelines. The company sells natural gas to electric utilities, independent power plants, local distribution companies, industrial end-users, and other marketing companies. Its midstream operations include ownership and operation of approximately 35,000 miles of in service natural gas pipelines, 31 natural gas processing plants, 21 natural gas treating facilities, and 4 natural gas conditioning facilities in Texas, New Mexico, West Virginia, Pennsylvania, and Louisiana; operation of natural gas gathering, oil pipeline, and oil stabilization facilities in South Texas, as well as a natural gas gathering system in Ohio; and transportation and supply of water to natural gas producers in Pennsylvania. The companys natural gas liquid (NGL) transportation and services operations include ownership of approximately 2,000 miles of NGL pipelines, three NGL processing plants, four NGL and propane fractionation facilities, and NGL storage facilities. It also sells gasoline and middle distillates at retail; operates convenience stores primarily on the east coast and in the Midwest region of the United States; and gathers, purchases, stores, transports, markets, and sells crude oil, NGLs, and refined products. In addition, it provides natural gas compression services; treating services, such as carbon dioxide and hydrogen sulfide removal, natural gas cooling, dehydration, and British thermal unit management services; and manages coal and natural resources properties, as well as sells standing timber, leases coal-related infrastructure facilities, collects oil and gas royalties, and generates a total of 75 megawatts electrical power. The company was founded in 2002 and is based in Dallas, Texas.
Allergan plc (AGN) shares were up in last trading by 1.35% to $210.01. It experienced lighter than average volume on day. The stock increased in value by almost 8.26% over the past week and grew 8.09% in the past month. It is currently trading 4.61% above its 50 day moving average and -8.66% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -33.85% decrease in value from its one year high of $310.83. The RSI indicator value of 67.67, lead us to believe that it is a hold for now.
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Brands, US Medical Aesthetics, International Brands, and Anda Distribution segments. The company offers a portfolio of products that provide treatments for the central nervous system, gastroenterology, womens health and urology, ophthalmology, neurosciences, medical aesthetics, liver disease, inflammation, fibrosis, and HIV, as well as dermatology and plastic surgery, and Alzheimers disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, it distributes generic and branded pharmaceutical products primarily to independent pharmacies, pharmacy chains, pharmacy buying groups, and physicians offices. Allergan plc has a collaboration with T2 Biosystems to develop blood-based diagnostic panel for the detection of Gram-negative bacterial species. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
HCP, Inc. (HCP) traded within a range of $29.33 to $29.84 after opening the day at $29.48. The company has seen its stock decrease in value by -9.45% so far this year. The stock was up close to 1.23% on light volume in last trading session and closed at $29.72 per share. After the recent gain, the stock is currently holding -18.29% below its 52 week high of $36.82 and 35.74% above its 12-month low of $22.87. The shares are down by over -12.95% in the last three months, and the RSI indicator value of 51.58 is neither bullish nor bearish, tempting investors to stay on the sidelines.
HCP, Inc. is an independent hybrid real estate investment trust. The fund invests in real estate markets of the United States. It primarily invests in properties serving the healthcare industry including sectors of healthcare such as senior housing, life science, medical office, hospital and skilled nursing. The fund also invests in mezzanine loans and other debt instruments. It engages in acquisition, development, leasing, selling and managing of healthcare real estate and provides mortgage and other financing to healthcare providers. The fund benchmarks the performance of its portfolio against the S&P 500 Index, Berkshire Hathaway Index, and MSCI REIT Index. HCP, Inc. was formed in 1985 and is based in Irvine, California with additional office in Nashville and San Francisco.